IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta-9-tetrahydrocannabinol June 10, 2024 Read More »
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1 May 28, 2024 Read More »
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two April 16, 2024 Read More »
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock March 26, 2024 Read More »
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation March 20, 2024 Read More »
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 March 20, 2024 Read More »
